Roberts Capital Advisors LLC Makes New Investment in Eli Lilly and Company $LLY

Roberts Capital Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,018 shares of the company’s stock, valued at approximately $1,540,000. Eli Lilly and Company accounts for 1.7% of Roberts Capital Advisors LLC’s portfolio, making the stock its 13th biggest holding.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Exencial Wealth Advisors LLC raised its position in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new stake in shares of Eli Lilly and Company during the third quarter worth $487,000. Central Pacific Bank Trust Division lifted its stake in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after acquiring an additional 1,843 shares during the period. Cidel Asset Management Inc. raised its stake in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after buying an additional 5,591 shares during the last quarter. Finally, Oak Family Advisors LLC acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $1,979,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will invest $3 billion in China over the next decade to expand supply‑chain and local manufacturing capacity — including production for its oral GLP‑1 orforglipron — which supports global supply resilience and access to China’s large diabetes/obesity market. Eli Lilly to invest $3 billion in China over next decade
• Positive Sentiment: Lilly has filed for approval of its new GLP‑1 treatment in China, a step that could accelerate launches of both injectable and oral therapies in a critical growth market. Eli Lilly plans $3 billion China investment, files for approval of new GLP-1 treatment
• Positive Sentiment: Clinical/program updates: Lilly reported completion of a Phase 1 study for a China program (LY3985863) and continues strong head‑to‑head data for oral orforglipron versus oral semaglutide — supporting market potential for a lower‑cost, high‑volume oral GLP‑1. Eli Lilly Advances New LY3985863 Program With Completion of Phase 1 Study in China
• Positive Sentiment: Access initiatives: Lilly launched Employer Connect to push employer coverage of obesity drugs (discounted pricing and PBM bypass). If widely adopted, this could materially expand payer coverage and volume (potential 2027 upside), though it may compress per‑unit margins. Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform
• Neutral Sentiment: Partnerships and R&D footprint expansion — Lilly is building a Gateway Labs hub with Samsung Biologics in South Korea and pledging regional investments, which support long‑term R&D sourcing and local talent pipelines but won’t drive immediate revenue. Eli Lilly Taps Samsung Biologics To Grow Korean Biotech And Long Term Value
• Neutral Sentiment: Industry movement: a former Lilly communications chief joined Hims & Hers — notable for competitive dynamics around obesity drugs and messaging but not a direct LLY revenue driver. Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift
• Negative Sentiment: Payer/regulatory pressure: Lilly warned some Medicare beneficiaries could still face out‑of‑pocket costs above $50 under a new CMS model because certain Part D plans may not fully meet the cap — a potential headwind for uptake and public optics. Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50
• Negative Sentiment: Marketing limits in key markets: India’s regulator warned against direct or surrogate advertising of weight‑loss drugs, which could restrict promotional channels and slow commercial rollout/awareness in a fast‑growing market. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

Analyst Upgrades and Downgrades

Several brokerages have commented on LLY. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,313.00 target price on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Berenberg Bank raised their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

LLY opened at $999.23 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The business has a 50 day moving average of $1,041.12 and a 200-day moving average of $947.08. The stock has a market cap of $944.10 billion, a price-to-earnings ratio of 43.54, a PEG ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.